Heparanase (HPSE) genetic variants as prognostic indicators in ovarian cancer: evidence from discovery and validation cohorts

Inês Guerra de Melo, Valéria Tavares, Joana Savva-Bordalo, Mariana Rei, Joana Liz-Pimenta, Deolinda Pereira, Rui Medeiros · 2026

Read Heparanase (HPSE) genetic variants as prognostic indicators in ovarian cancer: evidence from discovery and validation cohorts by Inês Guerra de Melo, Valéria Tavares, Joana Savva-Bordalo, Mariana Rei, Joana Liz-Pimenta, Deolinda Pereira, Rui Medeiros (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13144214.txt.

Description

Inês Guerra de Melo and co-authors test gene variants as outlook markers in ovarian cancer in this 2026 study. The gene makes heparanase, an enzyme that cuts a key cell-surface sugar. That cutting can help tumors spread, yet it can also expose them to immune attack.

Ovarian tumors often carry high levels of the enzyme, and the cancer clots blood at a high rate. Past work showed gene variants shift how much enzyme is made. The team checked those variants in a discovery group and a validation group. If the variants track with outcomes, they could guide prognosis. The study weighs a double-edged enzyme as a marker.

Catalog record

CREATORInês Guerra de Melo, Valéria Tavares, Joana Savva-Bordalo, Mariana Rei, Joana Liz-Pimenta, Deolinda Pereira, Rui Medeiros
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13144214

Browse the full library · About the Tower of Babel